KRAS and neoplasm: For example, in the case of some of the most studied genes in cancer41,42, we found that patients with tumours that harbour mutations in both KRAS and TP53 (p = 1.76 × 10–37) or CDKN1A and TP53 (p = 1.99 × 10–35) tended to exhibit worse survival outcomes than those with tumours in which one or none of these genes are mutated (Fig. 5b and 5c, see Supplementary Data 3).